MoneyWorks4Me

Suven Life Sciences informs about disclosure

02 Feb 2023 Evaluate
Suven Life Sciences has informed that it enclosed statement confirming that there were no deviation(s) or variation(s) in the use of proceeds, from the objects for which funds were raised through the preferential issue made by the Company, for the quarter ended 31st December, 2022.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1145.25
Cipla 1359.75
Lupin 2047.20
Zydus Lifesciences 1105.00
View more..